<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Genitourinary syndrome of menopause (vulvovaginal atrophy): Clinical manifestations and diagnosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Genitourinary syndrome of menopause (vulvovaginal atrophy): Clinical manifestations and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Genitourinary syndrome of menopause (vulvovaginal atrophy): Clinical manifestations and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gloria Bachmann, MD, MMS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">JoAnn V Pinkerton, MD, FACOG, NCMP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert L Barbieri, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 15, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Genitourinary syndrome of menopause (GSM) is defined as a collection of symptoms and signs caused by hypoestrogenic changes to the labia majora/minora, clitoris, vestibule/introitus, vagina, urethra, and bladder that occur in menopausal patients. The term GSM was introduced by the International Society for the Study of Women's Sexual Health and the North American Menopause Society in 2014 and replaced the term vaginal atrophy (other terms include vulvovaginal atrophy, urogenital atrophy, or atrophic vaginitis) [<a href="#rid1">1</a>]. The syndrome may include, but is not limited to, genital symptoms of dryness, burning, and irritation; sexual symptoms of lack of lubrication, discomfort or pain, and impaired function; and urinary symptoms of urgency, dysuria, and recurrent urinary tract infections. Patients may present with some or all of the signs and symptoms, which must be bothersome and should not be better accounted for by another diagnosis. The spectrum of adverse consequences requires long-term treatment in many patients. Treatment options include both hormonal and nonhormonal interventions.</p><p>Although vaginal atrophy typically occurs in menopausal patients, it can occur in females of any age who experience a decrease in estrogenic stimulation of the urogenital tissues. In premenopausal patients, a hypoestrogenic state may occur during the postpartum period or lactation or due to hypothalamic amenorrhea or antiestrogenic drugs. Not all patients with atrophic changes on examination are symptomatic. </p><p>Clinical manifestations and diagnosis of GSM are reviewed here. Treatment of symptomatic vaginal atrophy, as well as use of estrogen and other pharmacologic therapies for other menopausal symptoms, is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/5443.html" rel="external">"Genitourinary syndrome of menopause (vulvovaginal atrophy): Treatment"</a> and  <a class="medical medical_review" href="/d/html/7450.html" rel="external">"Treatment of menopausal symptoms with hormone therapy"</a> and  <a class="medical medical_review" href="/d/html/7446.html" rel="external">"Preparations for menopausal hormone therapy"</a> and  <a class="medical medical_review" href="/d/html/7427.html" rel="external">"Menopausal hormone therapy: Benefits and risks"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>Female urogenital atrophy results predominantly from a decline in serum estrogen levels. This is most commonly due to natural or surgical menopause but may also occur with premature ovarian insufficiency or, temporarily, during the postpartum period or lactation, or due to hypothalamic amenorrhea or antiestrogenic drugs. Androgens also appear to play a role in the maintenance of genitourinary tissue structure and function but are less well studied and appreciated. </p><p>The locations of these steroid receptors appear to vary within the genitourinary system. For example, estrogen receptor density appears higher in the vagina compared with the external genitalia, while androgen receptor density is lower in the vagina compared with the external genitalia. Progesterone receptors are found both in the vagina and transitional vulvovaginal area [<a href="#rid2">2,3</a>].</p><p class="headingAnchor" id="H1712840253"><span class="h2">Premenopausal physiology</span><span class="headingEndMark"> — </span>In premenopausal patients, estradiol is the predominant form of circulating estrogen. Serum estradiol concentrations in premenopausal patients fluctuate during the menstrual cycle  (<a class="graphic graphic_figure graphicRef72415" href="/d/graphic/72415.html" rel="external">figure 1</a>), as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Early follicular phase – An average of 50 pg/mL</p><p class="bulletIndent1"><span class="glyph">●</span>Ovulation – A range of 200 to 350 pg/mL</p><p class="bulletIndent1"><span class="glyph">●</span>Early luteal phase – An average of 100 pg/mL</p><p class="bulletIndent1"><span class="glyph">●</span>Mid-luteal phase – An average of 200 pg/mL</p><p class="bulletIndent1"><span class="glyph">●</span>Onset of menses – A range of 30 to 50 pg/mL</p><p></p><p>Estrogen stimulation is responsible for maintaining a well-epithelialized vaginal vault during the reproductive years. Estrogen acts on its receptors in the vagina, vulva, urethra, and trigone of the bladder to [<a href="#rid4">4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Maintain the collagen content of epithelium, which affects its thickness and elasticity</p><p class="bulletIndent1"><span class="glyph">●</span>Maintain acid mucopolysaccharides and hyaluronic acid, which keep epithelial surfaces moist</p><p class="bulletIndent1"><span class="glyph">●</span>Maintain optimal genital blood flow</p><p class="bulletIndent1"><span class="glyph">●</span>Maintain a healthy vaginal microbiome [<a href="#rid5">5</a>]</p><p></p><p>As a result, the nonkeratinized stratified squamous epithelium of the vagina in response to estrogen is thick, rugated, and rich in glycogen. Glycogen from sloughed cells is the substrate for Döderlein lactobacilli, which convert glucose into lactic acid, thereby creating an acidic vaginal environment. The acidity of the vagina helps maintain the normal vaginal flora and protects the urogenital area from vaginal and urinary tract infections [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H3128963104"><span class="h2">Effects of hypoestrogenism</span><span class="headingEndMark"> — </span>Menopause leads to a dramatic reduction in estrogen production, with an approximate 95 percent decline in estradiol levels from the premenopausal to postmenopausal state [<a href="#rid6">6</a>]. After menopause, serum estradiol concentrations plateau at levels averaging 5 pg/mL [<a href="#rid7">7</a>]. It should be noted that most estradiol assays are not sufficiently sensitive to detect postmenopausal estradiol levels accurately, and therefore, measurement of estradiol levels should not be a routine aspect of clinical care [<a href="#rid8">8</a>]. </p><p>The marked decrease in serum estrogen levels, exacerbated by the normal aging process, is responsible for many of the changes that comprise vaginal atrophy [<a href="#rid9">9,10</a>]. These changes usually develop gradually over a period of years. Hypoestrogenic vaginal changes may include:</p><p class="bulletIndent1"><span class="glyph">●</span>Thinning of the top layer of superficial epithelial cells; this layer may be completely absent in patients with severe atrophy</p><p class="bulletIndent1"><span class="glyph">●</span>Loss of rugae</p><p class="bulletIndent1"><span class="glyph">●</span>Loss of elasticity of the vaginal epithelium</p><p class="bulletIndent1"><span class="glyph">●</span>Shortening and narrowing of the vaginal canal, with loss of distensibility</p><p class="bulletIndent1"><span class="glyph">●</span>Increased subepithelial connective tissue</p><p class="bulletIndent1"><span class="glyph">●</span>Reduction in vaginal secretions from 3 to 4 g/4 hours to 1.7 g/4 hours</p><p class="bulletIndent1"><span class="glyph">●</span>Increase in vaginal pH to ≥5</p><p></p><p>Thinning of the vaginal epithelium increases susceptibility to trauma, resulting in bleeding, petechiae, and ulceration with pressure, including sexual activity or the performing of a Pap test  (<a class="graphic graphic_figure graphicRef71191" href="/d/graphic/71191.html" rel="external">figure 2</a>). Thinning also exposes the underlying connective tissue, which is more vulnerable to inflammation or infection. </p><p>The low glycogen content of the thinned epithelium leads to a reduction in lactic acid production by lactobacilli, resulting in an increase in vaginal pH [<a href="#rid11">11,12</a>]. These changes in the vaginal environment encourage the overgrowth of nonacidophilic coliforms and the reduction of lactobacillus species, thereby predisposing affected patients to infection by skin and rectal flora (eg, <em>Gardnerella vaginalis</em>, streptococci, staphylococci, coliforms, diphtheroids [<a href="#rid6">6</a>]), as well as trichomonas species. The shifting flora and resulting inflammatory changes were the source of the older term for this condition, atrophic vaginitis. However, although the vaginal microbiome in the menopausal patient appears to be related to vaginal health, there are no proven interventions to treat atrophic vaginitis through vaginal microbiome manipulation. Currently, no probiotic therapies have been validated to be an effective management intervention for GSM [<a href="#rid13">13</a>]. However, a combination of vaginal low-dose estriol and lactobacilli is an approved therapy in many countries other than the United States, but further study of this combination is needed [<a href="#rid14">14</a>].</p><p>Urinary tract structures are derived from the same embryologic origin as the genital tract and also contain estrogen receptors. Thus, the bladder, urethra, pelvic floor musculature, and endopelvic fascia are affected by a hypoestrogenic state. Possible consequences of atrophy of the urinary tract include urethral discomfort, urinary frequency, hematuria, dysuria, and an increased frequency of urinary tract infection.</p><p>Menopause increases the risk for both pelvic organ prolapse and stress urinary incontinence. While it might seem intuitive to use estrogen therapy for these issues, some data suggest that oral estrogen therapy results in the development or exacerbation of urinary incontinence. However, vaginal estrogen may improve continence [<a href="#rid15">15</a>], decrease urinary urgency or frequency symptoms, and decrease recurrent urinary tract infections. Systemic or vaginal estrogen does not appear to be effective as treatment of pelvic organ prolapse. (See  <a class="medical medical_review" href="/d/html/6881.html" rel="external">"Female urinary incontinence: Treatment", section on 'Topical vaginal estrogen'</a> and  <a class="medical medical_review" href="/d/html/8072.html" rel="external">"Pelvic organ prolapse in females: Epidemiology, risk factors, clinical manifestations, and management", section on 'Estrogen therapy'</a>.)</p><p>While the effects of estrogen loss on urogenital tissue have been well described, emerging data suggest that androgens also play a role in urogenital health, as androgen receptors have been reported in the mucosa, muscularis, and adventitial layers of the vagina [<a href="#rid16">16</a>]. Since there are both estrogen receptors and androgen receptors in the genitourinary tract of females, and androgens are precursors to the synthesis of estrogens, it can be conjectured that there is an indirect role of androgens on vulvovaginal health. The scant data available suggest androgens, such as <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a>, may have a direct effect on this tissue and not indirectly through the aromatization pathway [<a href="#rid3">3,17-19</a>]. </p><p class="headingAnchor" id="H719871"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H3"><span class="h2">Prevalence</span><span class="headingEndMark"> — </span>The prevalence of GSM is not well established. Most menopausal patients or patients in a hypoestrogenic state will develop urogenital atrophy. Representative studies include:</p><p class="bulletIndent1"><span class="glyph">●</span>Internet surveys suggest that vaginal dryness affects up to 85 percent of patients over 40 years of age, with an additional 29 to 59 percent reporting dyspareunia and another 26 to 77 percent reporting vaginal itching and irritation [<a href="#rid20">20,21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The prevalence of vaginal dryness symptoms by age group was best illustrated in a longitudinal study in which the symptoms were reported by 3 percent of patients of reproductive age, 4 percent of patients in early menopausal transition, 21 percent of patients in the later years of the menopausal transition, and 47 percent of patients three years after menopause [<a href="#rid22">22,23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An international survey of over 4000 menopausal patients reported that 39 percent had experienced menopause-related vaginal discomfort; 52 percent of those with vaginal discomfort reported that their quality of life had been affected by this symptom [<a href="#rid24">24</a>].</p><p></p><p class="headingAnchor" id="H4"><span class="h2">Etiology and modifying factors</span><span class="headingEndMark"> — </span>GSM occurs primarily in patients who are peri- or postmenopausal. Conditions or medications that induce a transient or chronic hypoestrogenic state can also cause atrophic vaginal changes. The duration of hypoestrogenism is a major factor in the development and severity of GSM. Etiologies of hypoestrogenism include:</p><p class="bulletIndent1"><span class="glyph">●</span>Natural menopause.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bilateral oophorectomy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Primary ovarian insufficiency.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ovarian failure due to radiation therapy, chemotherapy, or an adverse consequence of uterine artery embolization; these may be temporary or permanent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Premenopausal use of medications with antiestrogenic effects, such as <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a>, aromatase inhibitors, <a class="drug drug_general" data-topicid="9321" href="/d/drug information/9321.html" rel="external">danazol</a>, <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a>, gonadotropin-releasing hormone agonists (eg, <a class="drug drug_general" data-topicid="9549" href="/d/drug information/9549.html" rel="external">leuprolide</a>, <a class="drug drug_general" data-topicid="9673" href="/d/drug information/9673.html" rel="external">nafarelin</a>, <a class="drug drug_general" data-topicid="8500" href="/d/drug information/8500.html" rel="external">goserelin</a>) or antagonists (eg, <a class="drug drug_general" data-topicid="8666" href="/d/drug information/8666.html" rel="external">ganirelix</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Postpartum reduction in estrogen production, particularly during lactation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prolactin elevation due to hypothalamic-pituitary disorders with secondary reduction of estrogen secretion by the ovary.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypothalamic amenorrhea or amenorrhea in the setting of severe systemic lupus erythematosus or rheumatoid arthritis (due to hypothalamic hypogonadism or primary ovarian insufficiency) combined with glucocorticoid therapy – The combined suppression of ovarian and adrenal activity (loss of adrenal androstenedione reduces estradiol synthesized through extraovarian aromatization) results in extremely low estradiol levels.</p><p></p><p>Factors other than low estrogen and possibly diminished androgen levels can modulate the degree of vulvovaginal atrophy or the severity of symptoms. For example, vaginal nulliparity or vaginal surgery may intensify vaginal atrophy symptoms [<a href="#rid25">25,26</a>]. Abstinence from sexual activity appears to exacerbate atrophic changes whereas sexual activity helps preserve the vaginal epithelium, presumably by increasing blood flow and tissue elasticity. Cigarette smoking causes relative estrogen deficiency and may reduce vaginal perfusion [<a href="#rid4">4</a>].</p><p>Patients with depression and urinary incontinence may be more likely to report distressing vulvovaginal atrophy symptoms that more negatively impact their quality of life, including their sexual functioning. With urinary incontinence, this may be due to chronic perineal pad use [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H5"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>By definition, patients with GSM are symptomatic. However, not all patients with atrophic changes on pelvic examination are symptomatic. </p><p>Up to 70 percent of patients with symptoms of vaginal atrophy do not discuss their condition with a health care provider [<a href="#rid24">24</a>]; some believe their symptoms are an expected and necessary part of the aging process [<a href="#rid25">25</a>]. Cultural, religious, and societal beliefs, as well as embarrassment, may also play a role in making patients feel uncomfortable discussing concerns related to the genitourinary system. In addition, many patients are not aware of treatment options [<a href="#rid28">28</a>]. Rather than seeking treatment, patients commonly make lifestyle changes to deal with their symptoms. As an example, they may stop sexual activity due to dyspareunia caused by vaginal dryness, loss of vaginal elasticity, or development of levator spasm.</p><p>Symptoms of GSM include [<a href="#rid1">1,25</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Vulvovaginal dryness</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Decreased vaginal lubrication during sexual activity</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dyspareunia, including vulvar or vaginal pain (at the introitus or within the vagina)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vulvar or vaginal bleeding (eg, postcoital bleeding, labial fissures) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Decreased arousal, orgasm, or sexual desire</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vulvovaginal burning, irritation, or itching</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vaginal discharge (leukorrhea or yellow and malodorous)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Levator spasm</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Urinary tract symptoms (eg, urinary frequency, urinary urgency, dysuria, urethral discomfort, hematuria, recurrent urinary tract infections)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Urethral prolapse/caruncle</p><p></p><p>Symptoms accompanying vaginal atrophy are usually progressive and worsen as with duration of hypoestrogenism. Early in the menopause transition, patients may notice a slight decrease in vaginal lubrication upon sexual arousal, which is often one of the first signs of estrogen insufficiency. As the hypoestrogenic state becomes chronic, additional symptoms may be reported by the patient, including a sensation of vaginal dryness during daily activities, not necessarily during sexual activity (the most common symptom), and other symptoms (refer above) may develop. </p><p class="headingAnchor" id="H161668412"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>The evaluation for GSM typically includes both a medical history and a pelvic examination. Laboratory testing is not typically required. A telehealth visit may be utilized in some patients. (See  <a class="medical medical_review" href="/d/html/128313.html" rel="external">"Telemedicine for adults"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">History</span><span class="headingEndMark"> — </span>Patients who are peri- or postmenopausal or who have other etiologies of hypoestrogenism should be asked about symptoms of urogenital atrophy during routine clinical visits. As noted above, many patients with these symptoms do not bring them to the attention of a clinician [<a href="#rid24">24</a>]. (See <a class="local">'Clinical presentation'</a> above.)</p><p>A medical history should include the obstetric and gynecologic history, including menstrual history, and other conditions or medications to assess menopausal status and evaluate for etiologies of low estrogen other than menopause. The clinician should ask about response to any previous interventions. A complete review of systems should be performed, as urogenital symptoms may be due to etiologies other than loss of estrogen. A pertinent sexual history, including a history of sexual trauma, should be taken to evaluate whether the symptoms adversely impact sexual activity and cause distress. </p><p>The clinician should ask about painful vulvar symptoms, symptoms that may be associated with infection or inflammatory conditions (as part of a differential diagnosis), as well as use of products that may be irritants or result in allergic reactions (eg, perfumes, powders, panty liners, soaps, deodorants, spermicides, lubricants, tight clothing) [<a href="#rid29">29</a>]. This should also include a history of pelvic radiation. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>Quality of life issues should also be assessed; these include degree of discomfort, behavioral responses to symptoms, as well as the impact of symptoms on daily activities, sexual activity, and partner relationships [<a href="#rid30">30</a>]. The clinician should ask about the patient's therapeutic goals. Patients who are not having vaginal intercourse due to pain or discomfort should be asked if this is something they would like to be able to have in the future, recognizing that there are often multiple factors (eg, relationship status, aging, partner sexual dysfunction, lack of interest) that affect this decision.</p><p class="headingAnchor" id="H8"><span class="h2">Pelvic examination</span><span class="headingEndMark"> — </span>Signs associated with GSM include [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Labia minora resorption or fusion</p><p class="bulletIndent1"><span class="glyph">●</span>Tissue fragility/fissures/petechiae</p><p class="bulletIndent1"><span class="glyph">●</span>Introital retraction</p><p class="bulletIndent1"><span class="glyph">●</span>Loss of hymenal remnants</p><p class="bulletIndent1"><span class="glyph">●</span>Prominence of urethral meatus</p><p class="bulletIndent1"><span class="glyph">●</span>Urethral eversion or prolapse</p><p class="bulletIndent1"><span class="glyph">●</span>Vulvovaginal pallor/erythema</p><p class="bulletIndent1"><span class="glyph">●</span>Loss of vaginal rugae</p><p class="bulletIndent1"><span class="glyph">●</span>Decreased vulvovaginal secretions/lubrication</p><p class="bulletIndent1"><span class="glyph">●</span>Decreased elasticity</p><p class="bulletIndent1"><span class="glyph">●</span>Abnormal discharge</p><p class="bulletIndent1"><span class="glyph">●</span>Spasm of levator muscles on palpation of the posterior vagina</p><p></p><p>The external genitalia are examined and may show scarce pubic hair, diminished elasticity, and turgor of the vulvar skin; introital narrowing or decreased moisture; and fusion or resorption of the labia minora [<a href="#rid31">31,32</a>]. Some practitioners have the patient hold a mirror during the pelvic examination so that areas of vulvovaginal irritation or pain can be mutually noted. In severe cases, the labia majora may be fused [<a href="#rid25">25</a>]. It is necessary to exclude lichen sclerosus when there are structural changes like fused labia minora and loss of the clitoral hood. Loss of the labial fat pad gives the labia majora a pendulous appearance and makes the labia minora less distinct and/or makes the clitoris appear more protuberant. A urethral caruncle may be present and appear as proliferative red tissue at the opening of the urethra. Urethral prolapse or polyps may also occur. (See  <a class="medical medical_review" href="/d/html/5558.html" rel="external">"Vulvar lichen sclerosus: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/5430.html" rel="external">"Urethral caruncle"</a>.)</p><p>In patients with severe atrophic changes, exercise caution when performing the speculum and bimanual examinations as even gentle contact can cause pain and bleeding. Assess for introital stenosis using a gloved finger before attempting insertion of the speculum. Levator spasm may make insertion of a gloved finger too uncomfortable; instead of a two-finger pelvic exam, a one-finger gloved examination is often better tolerated by the patient. A lubricated narrow speculum is also usually most comfortable. Thus, among metal speculums, a Pederson is usually chosen rather than a Graves speculum  (<a class="graphic graphic_picture graphicRef78911" href="/d/graphic/78911.html" rel="external">picture 1</a>). A narrow Pederson speculum or a pediatric speculum may be necessary for examining some patients. If the insertion of a gloved finger or speculum is too distressing for the patient, then it is best to stop the examination and ask the patient if she is too uncomfortable to continue. For some patients, treatment of the vaginal atrophy may be necessary before a complete pelvic examination can be performed. Rectal examination or transabdominal pelvic ultrasound may allow evaluation of uterus and organs when the vagina is too stenotic or the examination is too uncomfortable. When an office examination cannot be comfortably completed and is deemed essential before management can begin, and an adequate ultrasound that excludes pathology is not possible, an examination under anesthesia may be necessary.</p><p>Classic vaginal findings of atrophy include a pale, dry vaginal epithelium that is smooth and shiny with loss of most rugation. If inflammation is present, there may be patchy erythema, petechiae, blood vessels visible through the thinned epithelium, friability, bleeding, and discharge. The vagina may be shortened, narrowed, and poorly distensible. The cervix may become flush with the vault, and it may be difficult to identify the cervix or the cervical os. The vaginal fornices may become obliterated. The urethra is often prominent due to loss of collagen support and eversion of urethral mucosa may occur.</p><p class="headingAnchor" id="H9"><span class="h2">Laboratory evaluation</span><span class="headingEndMark"> — </span>Laboratory tests are usually not necessary for the diagnosis and evaluation of GSM, other than for exclusion of other etiologies under consideration or to assess the efficacy of treatments in research studies.</p><p class="bulletIndent1"><span class="glyph">●</span>Vaginal pH – The pH of an estrogenized vagina is acidic, typically in the range of 4 to 4.5 [<a href="#rid33">33,34</a>], though broader ranges (3.5 to 5) have been reported [<a href="#rid35">35</a>]. Vaginal pH may reach levels of 5.5 to 6.8 or higher in postmenopausal patients, especially those who are not on estrogen therapy [<a href="#rid36">36</a>]. Thus, a pH of ≥5 in the absence of other causes (eg, infection, semen in setting of recent intercourse) can be an indicator of vaginal atrophy due to estrogen deficiency. The pH should be documented in the chart and also allows the patient to see the effects of lack of estrogen on the vaginal pH. This is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/5477.html" rel="external">"Vaginitis in adults: Initial evaluation", section on 'Normal vaginal discharge'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Maturation index – The maturation index is the proportion of parabasal, intermediate, and superficial cells in each 100 cells counted on a smear of the upper two-thirds of the vagina. It is used to quantify the proportions of cell types of the vaginal epithelium [<a href="#rid37">37</a>]. It is usually done in a laboratory experienced in running this test. In premenopausal patients with adequate estrogen levels, intermediate and superficial cells predominate. The maturation index for these patients is typically 40 to 70 intermediate cells, 30 to 60 superficial cells, and 0 parabasal cells. In patients with vaginal atrophy, an increase in parabasal cells and a decrease in superficial cells are observed. Patients in early menopause typically have a maturation index of 65 parabasal cells, 30 intermediate cells, and 5 superficial cells. As patients age, parabasal cells will continue to increase, and the maturation index may eventually consist entirely of parabasal cells. </p><p></p><p>If vaginitis is suspected, microscopy or other testing should be performed. Yeast or clue cells may indicate need for treatment. If urinary tract infection is suspected, this should be evaluated as appropriate. (See  <a class="medical medical_review" href="/d/html/5477.html" rel="external">"Vaginitis in adults: Initial evaluation", section on 'Test vaginal discharge'</a> and  <a class="medical medical_review" href="/d/html/8063.html" rel="external">"Acute simple cystitis in adult and adolescent females", section on 'Diagnostic approach'</a>.)</p><p class="headingAnchor" id="H1022664662"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>GSM is a clinical diagnosis made in patients who are in a hypoestrogenic state and have characteristic symptoms and findings on pelvic examination. Patients may present with some or all of the signs and symptoms, which must be bothersome and should not be better accounted for by another diagnosis. </p><p>The presence of symptoms in a perimenopausal or postmenopausal patient is sufficient since physical findings may not be present after a short duration of low estrogen. Laboratory tests to confirm hypoestrogenic findings are available, but such testing is typically not necessary.</p><p class="headingAnchor" id="H10"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of symptomatic urogenital atrophy includes other causes of vulvovaginal discomfort, scarring, or discharge or urinary symptoms [<a href="#rid29">29,30</a>]. These include: </p><p class="bulletIndent1"><span class="glyph">●</span>Vaginitis and vaginosis (eg, candidiasis, bacterial vaginosis, trichomoniasis, desquamative inflammatory vaginitis). (See  <a class="medical medical_review" href="/d/html/5477.html" rel="external">"Vaginitis in adults: Initial evaluation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vulvar dermatitis in response to environmental agents (eg, perfumes, deodorants, soaps, panty liners, perineal pads, spermicides, lubricants, or tight-fitting/synthetic clothing) resulting in contact or irritant dermatitis. (See  <a class="medical medical_review" href="/d/html/5563.html" rel="external">"Vulvar dermatitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vulvar lichen sclerosus. (See  <a class="medical medical_review" href="/d/html/5558.html" rel="external">"Vulvar lichen sclerosus: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vulvovaginal lichen planus. (See  <a class="medical medical_review" href="/d/html/5557.html" rel="external">"Vulvar lichen planus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Genital tract ulcers or fissures may be due to herpes lesions or systemic disease (eg, Crohn disease). (See  <a class="medical medical_review" href="/d/html/128406.html" rel="external">"Vulvar lesions: Differential diagnosis of red lesions", section on 'Crohn disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Genital tract bleeding may be due to trauma, infection, or malignancy. Females with postcoital bleeding should be evaluated for cervical cancer. (See  <a class="medical medical_review" href="/d/html/5412.html" rel="external">"Vulvar lesions: Differential diagnosis of vesicles, bullae, erosions, and ulcers", section on 'Trauma (physical and chemical)'</a> and  <a class="medical medical_review" href="/d/html/5440.html" rel="external">"Causes of female genital tract bleeding"</a> and  <a class="medical medical_review" href="/d/html/128407.html" rel="external">"Vulvar lesions: Differential diagnosis of white lesions", section on 'Squamous cell carcinoma'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vulvodynia. (See  <a class="medical medical_review" href="/d/html/5413.html" rel="external">"Vulvar pain of unknown cause (vulvodynia): Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other etiologies of frequent urinary tract infection or associated symptoms (eg, anatomic or hygiene issues, bladder pain syndrome). (See  <a class="medical medical_review" href="/d/html/8053.html" rel="external">"Recurrent simple cystitis in women"</a> and  <a class="medical medical_review" href="/d/html/8085.html" rel="external">"Interstitial cystitis/bladder pain syndrome: Clinical features and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H2413579196"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113098.html" rel="external">"Society guideline links: Menopause"</a>.)</p><p class="headingAnchor" id="H23842075"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/17105.html" rel="external">"Patient education: Vaginal dryness (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H12"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Genitourinary syndrome of menopause (GSM) is defined as a collection of symptoms and signs associated with a decrease in estrogen and other sex steroids involving changes to the labia majora/minora, clitoris, vestibule/introitus, vagina, urethra, and bladder. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Female urogenital atrophy results primarily from a decline in the serum estrogen concentration. This is most commonly due to natural or surgical menopause but may also occur with premature ovarian insufficiency or, temporarily, during the postpartum period or lactation or due to hypothalamic amenorrhea or antiestrogenic drugs. The likelihood and severity of symptoms increases with duration of hypoestrogenism. Loss of serum androgen concentration also appears to play a role. (See <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Symptoms may include vulvovaginal dryness, burning, and irritation; sexual symptoms of lack of lubrication, discomfort or pain, and impaired function; and urinary symptoms of urgency, dysuria, and recurrent urinary tract infections. Approximately 50 percent of menopausal patients report bothersome vulvovaginal discomfort. Many patients have symptoms but do not seek medical care; thus, clinicians should ask menopausal patients if they have pain, itching, or sexual symptoms during routine well-women checkups. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The evaluation includes a medical history and pelvic examination; a telehealth visit may be utilized in some patients. Laboratory testing is not typically necessary. Pelvic examination findings may include tissue fragility/fissures/petechiae; labia minora resorption or fusion; introital retraction; loss of vaginal moisture, rugae, and elasticity; urethral meatus appears prominent; and urethral eversion or prolapse. A single-finger gloved examination may be more comfortable than a bidigital examination. Rectal examination may provide additional information if vaginal examination is limited. However, for some patients with severe atrophic changes, treatment of the vaginal atrophy may be necessary before a complete pelvic examination can be performed. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>GSM is a clinical diagnosis made in patients who are in a hypoestrogenic state and have characteristic symptoms and findings on pelvic examination. Patients may present with some or all of the signs and symptoms, which must be bothersome and should not be better accounted for by another diagnosis. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The differential diagnosis of symptomatic urogenital atrophy includes other causes of vulvovaginal discomfort, scarring, or discharge or urinary symptoms, including vaginitis; vulvar lichen sclerosus; vulvovaginal lichen planus; vulvar contact or irritant dermatitis; genital ulcers or fissures due to herpes lesions or systemic disease; genital tract bleeding due to trauma, infection, or malignancy; other etiologies of urinary tract infection; or associated symptoms. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="headingAnchor" id="H3768020757"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Richard Santen, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Portman DJ, Gass ML, Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. Menopause 2014; 21:1063.</a></li><li><a class="nounderline abstract_t">The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause 2020; 27:976.</a></li><li><a class="nounderline abstract_t">Simon JA, Goldstein I, Kim NN, et al. The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review. Menopause 2018; 25:837.</a></li><li><a class="nounderline abstract_t">Castelo-Branco C, Cancelo MJ, Villero J, et al. Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas 2005; 52 Suppl 1:S46.</a></li><li><a class="nounderline abstract_t">Auriemma RS, Scairati R, Del Vecchio G, et al. The Vaginal Microbiome: A Long Urogenital Colonization Throughout Woman Life. Front Cell Infect Microbiol 2021; 11:686167.</a></li><li><a class="nounderline abstract_t">Pandit L, Ouslander JG. Postmenopausal vaginal atrophy and atrophic vaginitis. Am J Med Sci 1997; 314:228.</a></li><li><a class="nounderline abstract_t">Lee JS, Ettinger B, Stanczyk FZ, et al. Comparison of methods to measure low serum estradiol levels in postmenopausal women. J Clin Endocrinol Metab 2006; 91:3791.</a></li><li><a class="nounderline abstract_t">Demers LM, Hankinson SE, Haymond S, et al. Measuring Estrogen Exposure and Metabolism: Workshop Recommendations on Clinical Issues. J Clin Endocrinol Metab 2015; 100:2165.</a></li><li><a class="nounderline abstract_t">Greendale GA, Judd HL. The menopause: health implications and clinical management. J Am Geriatr Soc 1993; 41:426.</a></li><li><a class="nounderline abstract_t">Forsberg JG. A morphologist's approach to the vagina--age-related changes and estrogen sensitivity. Maturitas 1995; 22 Suppl:S7.</a></li><li><a class="nounderline abstract_t">Miller EA, Beasley DE, Dunn RR, Archie EA. Lactobacilli Dominance and Vaginal pH: Why Is the Human Vaginal Microbiome Unique? Front Microbiol 2016; 7:1936.</a></li><li><a class="nounderline abstract_t">Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc 2010; 85:87.</a></li><li><a class="nounderline abstract_t">Muhleisen AL, Herbst-Kralovetz MM. Menopause and the vaginal microbiome. Maturitas 2016; 91:42.</a></li><li><a class="nounderline abstract_t">Mueck AO, Ruan X, Prasauskas V, et al. Treatment of vaginal atrophy with estriol and lactobacilli combination: a clinical review. Climacteric 2018; 21:140.</a></li><li><a class="nounderline abstract_t">Rahn DD, Carberry C, Sanses TV, et al. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol 2014; 124:1147.</a></li><li><a class="nounderline abstract_t">Labrie F, Martel C, Pelletier G. Is vulvovaginal atrophy due to a lack of both estrogens and androgens? Menopause 2017; 24:452.</a></li><li><a class="nounderline abstract_t">Witherby S, Johnson J, Demers L, et al. Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study. Oncologist 2011; 16:424.</a></li><li><a class="nounderline abstract_t">Fernandes T, Costa-Paiva LH, Pedro AO, et al. Efficacy of vaginally applied estrogen, testosterone, or polyacrylic acid on vaginal atrophy: a randomized controlled trial. Menopause 2016; 23:792.</a></li><li><a class="nounderline abstract_t">Melisko ME, Goldman ME, Hwang J, et al. Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial. JAMA Oncol 2017; 3:313.</a></li><li><a class="nounderline abstract_t">Krychman M, Graham S, Bernick B, et al. The Women's EMPOWER Survey: Women's Knowledge and Awareness of Treatment Options for Vulvar and Vaginal Atrophy Remains Inadequate. J Sex Med 2017; 14:425.</a></li><li><a class="nounderline abstract_t">Huang AJ, Gregorich SE, Kuppermann M, et al. Day-to-Day Impact of Vaginal Aging questionnaire: a multidimensional measure of the impact of vaginal symptoms on functioning and well-being in postmenopausal women. Menopause 2015; 22:144.</a></li><li><a class="nounderline abstract_t">Dennerstein L, Dudley EC, Hopper JL, et al. A prospective population-based study of menopausal symptoms. Obstet Gynecol 2000; 96:351.</a></li><li><a class="nounderline abstract_t">Woods NF, Mitchell ES. Symptoms during the perimenopause: prevalence, severity, trajectory, and significance in women's lives. Am J Med 2005; 118 Suppl 12B:14.</a></li><li><a class="nounderline abstract_t">Nappi RE, Kokot-Kierepa M. Women's voices in the menopause: results from an international survey on vaginal atrophy. Maturitas 2010; 67:233.</a></li><li><a class="nounderline abstract_t">Bachmann GA, Nevadunsky NS. Diagnosis and treatment of atrophic vaginitis. Am Fam Physician 2000; 61:3090.</a></li><li><a class="nounderline abstract_t">Rangiah K, Shah SJ, Vachani A, et al. Liquid chromatography/mass spectrometry of pre-ionized Girard P derivatives for quantifying estrone and its metabolites in serum from postmenopausal women. Rapid Commun Mass Spectrom 2011; 25:1297.</a></li><li><a class="nounderline abstract_t">Hunter MM, Nakagawa S, Van Den Eeden SK, et al. Predictors of impact of vaginal symptoms in postmenopausal women. Menopause 2016; 23:40.</a></li><li><a class="nounderline abstract_t">Kingsberg SA, Schaffir J, Faught BM, et al. Female Sexual Health: Barriers to Optimal Outcomes and a Roadmap for Improved Patient-Clinician Communications. J Womens Health (Larchmt) 2019; 28:432.</a></li><li><a class="nounderline abstract_t">Beard MK. Atrophic vaginitis. Can it be prevented as well as treated? Postgrad Med 1992; 91:257.</a></li><li><a class="nounderline abstract_t">North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause 2007; 14:355.</a></li><li><a class="nounderline abstract_t">Johnston SL, Farrell SA, Bouchard C, et al. The detection and management of vaginal atrophy. J Obstet Gynaecol Can 2004; 26:503.</a></li><li><a class="nounderline abstract_t">Oriba HA, Maibach HI. Vulvar transepidermal water loss (TEWL) decay curves. Effect of occlusion, delipidation, and age. Acta Derm Venereol 1989; 69:461.</a></li><li><a class="nounderline abstract_t">Hill LV, Embil JA. Vaginitis: current microbiologic and clinical concepts. CMAJ 1986; 134:321.</a></li><li><a class="nounderline abstract_t">Murta EF, Filho AC, Barcelos AC. Relation between vaginal and endocervical pH in pre- and post-menopausal women. Arch Gynecol Obstet 2005; 272:211.</a></li><li><a class="nounderline abstract_t">Lin YP, Chen WC, Cheng CM, Shen CJ. Vaginal pH Value for Clinical Diagnosis and Treatment of Common Vaginitis. Diagnostics (Basel) 2021; 11.</a></li><li><a class="nounderline abstract_t">Nilsson K, Risberg B, Heimer G. The vaginal epithelium in the postmenopause--cytology, histology and pH as methods of assessment. Maturitas 1995; 21:51.</a></li><li><a class="nounderline abstract_t">Willhite LA, O'Connell MB. Urogenital atrophy: prevention and treatment. Pharmacotherapy 2001; 21:464.</a></li></ol></div><div id="topicVersionRevision">Topic 5464 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25160739" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32852449" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29870471" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16139449" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Management of post-menopausal vaginal atrophy and atrophic vaginitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34295836" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The Vaginal Microbiome: A Long Urogenital Colonization Throughout Woman Life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9332260" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Postmenopausal vaginal atrophy and atrophic vaginitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16882749" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Comparison of methods to measure low serum estradiol levels in postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25850026" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Measuring Estrogen Exposure and Metabolism: Workshop Recommendations on Clinical Issues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8463532" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The menopause: health implications and clinical management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8775771" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A morphologist's approach to the vagina--age-related changes and estrogen sensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28008325" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Lactobacilli Dominance and Vaginal pH: Why Is the Human Vaginal Microbiome Unique?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20042564" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Vulvovaginal atrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27451320" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Menopause and the vaginal microbiome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29381086" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Treatment of vaginal atrophy with estriol and lactobacilli combination: a clinical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25415166" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Vaginal estrogen for genitourinary syndrome of menopause: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27875388" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Is vulvovaginal atrophy due to a lack of both estrogens and androgens?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21385795" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27116462" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Efficacy of vaginally applied estrogen, testosterone, or polyacrylic acid on vaginal atrophy: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27832260" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28202319" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The Women's EMPOWER Survey: Women's Knowledge and Awareness of Treatment Options for Vulvar and Vaginal Atrophy Remains Inadequate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24983271" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Day-to-Day Impact of Vaginal Aging questionnaire: a multidimensional measure of the impact of vaginal symptoms on functioning and well-being in postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10960625" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A prospective population-based study of menopausal symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16414323" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Symptoms during the perimenopause: prevalence, severity, trajectory, and significance in women's lives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20828948" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Women's voices in the menopause: results from an international survey on vaginal atrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10839558" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Diagnosis and treatment of atrophic vaginitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21488127" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Liquid chromatography/mass spectrometry of pre-ionized Girard P derivatives for quantifying estrone and its metabolites in serum from postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26173074" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Predictors of impact of vaginal symptoms in postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30714849" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Female Sexual Health: Barriers to Optimal Outcomes and a Roadmap for Improved Patient-Clinician Communications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1579532" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Atrophic vaginitis. Can it be prevented as well as treated?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17438512" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15151738" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The detection and management of vaginal atrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2575316" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Vulvar transepidermal water loss (TEWL) decay curves. Effect of occlusion, delipidation, and age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3510698" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Vaginitis: current microbiologic and clinical concepts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15838694" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Relation between vaginal and endocervical pH in pre- and post-menopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34829343" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Vaginal pH Value for Clinical Diagnosis and Treatment of Common Vaginitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7731384" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The vaginal epithelium in the postmenopause--cytology, histology and pH as methods of assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11310520" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Urogenital atrophy: prevention and treatment.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
